Don't want ads? Subscribe or login now.

Health Plans Defend Renewed Biogen MS Drug Scheme Suit

By Lauraann Wood · November 26, 2025, 8:29 PM EST

Health plans claiming Biogen Inc. illegally stifled competition for its multiple sclerosis drug Tecfidera have said an Illinois federal judge should let their latest complaint proceed to discovery because it fixes...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response

Case Information

Case Title

IN RE: TECFIDERA ANTITRUST LITIGATION

Case Number

1:24-cv-07387

Court

Illinois Northern

Nature of Suit

410 Anti-Trust

Date Filed

August 16, 2024

Recent Articles By Lauraann

November 18, 2025
'Surrender' Note Warrants Med Mal Retrial, Ill. Justices Hear
November 10, 2025
GTCR's $627M Medical Coatings Acquisition Can Get Moving
October 22, 2025
Ex-Beverly Hills Housewife Boots Defamation Counterclaim
October 15, 2025
Bankruptcy Can't End Caterpillar Privacy Suit, Ex-Worker Says
October 02, 2025
UChicago Medicine Ducks Class Claims In Patient Privacy Suit
September 30, 2025
Ill. Doctor Gets Two Years' Probation For $4M Medicare Fraud
September 30, 2025
Blue Cross Insurers Sanctioned For 2-Year Discovery Drawout
September 29, 2025
CTA Could Face Second Ill. Jury Over Vaccine Bias Allegations
September 23, 2025
EX-CTA Worker's $425K Vaccine Bias Award Capped At $300K
September 11, 2025
7th Circ. Backs $183M FCA Award Over Eli Lilly Drug Rebates